Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Crystal structures of sampatrilat and sampatrilat-Asp in complex with human ACE - a molecular basis for domain selectivity.

Cozier GE, Schwager SL, Sharma RK, Chibale K, Sturrock ED, Acharya KR.

FEBS J. 2018 Apr;285(8):1477-1490. doi: 10.1111/febs.14421. Epub 2018 Mar 8.

2.

Investigation into the Mechanism of Homo- and Heterodimerization of Angiotensin-Converting Enzyme.

Abrie JA, Moolman WJA, Cozier GE, Schwager SL, Acharya KR, Sturrock ED.

Mol Pharmacol. 2018 Apr;93(4):344-354. doi: 10.1124/mol.117.110866. Epub 2018 Jan 25. Erratum in: Mol Pharmacol. 2018 May;93(5):416.

PMID:
29371233
3.

The Design and Development of a Potent and Selective Novel Diprolyl Derivative That Binds to the N-Domain of Angiotensin-I Converting Enzyme.

Fienberg S, Cozier GE, Acharya KR, Chibale K, Sturrock ED.

J Med Chem. 2018 Jan 11;61(1):344-359. doi: 10.1021/acs.jmedchem.7b01478. Epub 2017 Dec 21.

PMID:
29206036
4.

Therapeutic drug monitoring of amlodipine and the Z-FHL/HHL ratio: Adherence tools in patients referred for apparent treatment-resistant hypertension.

Jones ESW, Lesosky M, Blockman M, Castel S, Decloedt EH, Schwager SLU, Sturrock ED, Wiesner L, Rayner BL.

S Afr Med J. 2017 Sep 22;107(10):887-891. doi: 10.7196/SAMJ.2017.v107i10.12268.

5.

The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme.

Sharma RK, Espinoza-Moraga M, Poblete H, Douglas RG, Sturrock ED, Caballero J, Chibale K.

J Chem Inf Model. 2016 Dec 27;56(12):2486-2494. doi: 10.1021/acs.jcim.6b00524. Epub 2016 Dec 13.

PMID:
27959521
6.

The effect of structural motifs on the ectodomain shedding of human angiotensin-converting enzyme.

Conrad N, Schwager SL, Carmona AK, Sturrock ED.

Biochem Biophys Res Commun. 2016 Dec 2;481(1-2):111-116. doi: 10.1016/j.bbrc.2016.10.155. Epub 2016 Nov 3.

PMID:
27818199
7.

The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition.

Lubbe L, Sewell BT, Sturrock ED.

FEBS J. 2016 Nov;283(21):3941-3961. doi: 10.1111/febs.13900. Epub 2016 Oct 5.

8.

Letter to the editor: Angiotensin quantification by mass spectrometry.

Poglitsch M, Sturrock ED, Danser AH.

Am J Physiol Heart Circ Physiol. 2016 Feb 1;310(3):H452-3. doi: 10.1152/ajpheart.00933.2015. No abstract available.

9.

Kinetic and structural characterization of amyloid-β peptide hydrolysis by human angiotensin-1-converting enzyme.

Larmuth KM, Masuyer G, Douglas RG, Schwager SL, Acharya KR, Sturrock ED.

FEBS J. 2016 Mar;283(6):1060-76. doi: 10.1111/febs.13647. Epub 2016 Feb 9.

10.

Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme.

Masuyer G, Douglas RG, Sturrock ED, Acharya KR.

Sci Rep. 2015 Sep 25;5:13742. doi: 10.1038/srep13742.

11.

Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats.

Sharp S, Poglitsch M, Zilla P, Davies NH, Sturrock ED.

J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):1149-58. doi: 10.1177/1470320314568438. Epub 2015 Mar 9.

PMID:
25757657
12.

Angiotensin-I converting enzyme (ACE): structure, biological roles, and molecular basis for chloride ion dependence.

Masuyer G, Yates CJ, Sturrock ED, Acharya KR.

Biol Chem. 2014 Oct;395(10):1135-49. doi: 10.1515/hsz-2014-0157. Review.

PMID:
25205727
13.

Highlight: the protease web.

Sturrock E, Sommerhoff CP.

Biol Chem. 2014 Oct;395(10):1133. doi: 10.1515/hsz-2014-0237. No abstract available.

PMID:
25153595
14.

Interkingdom pharmacology of Angiotensin-I converting enzyme inhibitor phosphonates produced by actinomycetes.

Kramer GJ, Mohd A, Schwager SL, Masuyer G, Acharya KR, Sturrock ED, Bachmann BO.

ACS Med Chem Lett. 2014 Feb 4;5(4):346-51. doi: 10.1021/ml4004588. eCollection 2014 Apr 10.

15.

Pharmacokinetic evaluation of lisinopril-tryptophan, a novel C-domain ACE inhibitor.

Denti P, Sharp SK, Kröger WL, Schwager SL, Mahajan A, Njoroge M, Gibhard L, Smit I, Chibale K, Wiesner L, Sturrock ED, Davies NH.

Eur J Pharm Sci. 2014 Jun 2;56:113-9. doi: 10.1016/j.ejps.2014.01.012. Epub 2014 Feb 20.

PMID:
24561703
16.

Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension.

Burger D, Reudelhuber TL, Mahajan A, Chibale K, Sturrock ED, Touyz RM.

Clin Sci (Lond). 2014 Jul;127(1):57-63. doi: 10.1042/CS20130808.

PMID:
24506807
17.

A novel angiotensin I-converting enzyme mutation (S333W) impairs N-domain enzymatic cleavage of the anti-fibrotic peptide, AcSDKP.

Danilov SM, Wade MS, Schwager SL, Douglas RG, Nesterovitch AB, Popova IA, Hogarth KD, Bhardwaj N, Schwartz DE, Sturrock ED, Garcia JG.

PLoS One. 2014 Feb 4;9(2):e88001. doi: 10.1371/journal.pone.0088001. eCollection 2014.

18.

Molecular and thermodynamic mechanisms of the chloride-dependent human angiotensin-I-converting enzyme (ACE).

Yates CJ, Masuyer G, Schwager SL, Akif M, Sturrock ED, Acharya KR.

J Biol Chem. 2014 Jan 17;289(3):1798-814. doi: 10.1074/jbc.M113.512335. Epub 2013 Dec 2.

19.

Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme.

Masuyer G, Akif M, Czarny B, Beau F, Schwager SL, Sturrock ED, Isaac RE, Dive V, Acharya KR.

FEBS J. 2014 Feb;281(3):943-56. doi: 10.1111/febs.12660. Epub 2013 Dec 24.

20.

Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors.

Douglas RG, Sharma RK, Masuyer G, Lubbe L, Zamora I, Acharya KR, Chibale K, Sturrock ED.

Clin Sci (Lond). 2014 Feb;126(4):305-13. doi: 10.1042/CS20130403.

21.

Association of B2 receptor polymorphisms and ACE activity with ACE inhibitor-induced angioedema in black and mixed-race South Africans.

Moholisa RR, Rayner BR, Patricia Owen E, Schwager SL, Stark JS, Badri M, Cupido CL, Sturrock ED.

J Clin Hypertens (Greenwich). 2013 Jun;15(6):413-9. doi: 10.1111/jch.12104. Epub 2013 Apr 11.

22.

C domain-selective inhibition of angiotensin-converting enzyme.

Ehlers MR, Abrie JA, Sturrock ED.

J Renin Angiotensin Aldosterone Syst. 2013 Jun;14(2):189-92. doi: 10.1177/1470320313489206. No abstract available.

PMID:
23686914
23.

Characterization of angiotensin I-converting enzyme N-domain selectivity using positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides.

Bersanetti PA, Sabatini RA, Matos BS, Douglas RG, Nchinda A, Juliano MA, Pesquero JB, Sturrock ED, Carmona AK.

Biol Chem. 2012 Dec;393(12):1547-54.

PMID:
23667908
24.

Antifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design.

Douglas RG, Ehlers MR, Sturrock ED.

Clin Exp Pharmacol Physiol. 2013 Aug;40(8):535-41. doi: 10.1111/1440-1681.12062. Review.

PMID:
23351021
25.

ACE activity and endurance performance during the South African Ironman triathlons.

Domingo R, Sturrock ED, Collins M.

Int J Sports Med. 2013 May;34(5):402-8. doi: 10.1055/s-0032-1323820. Epub 2012 Oct 22.

PMID:
23090675
26.

Structural basis of peptide recognition by the angiotensin-1 converting enzyme homologue AnCE from Drosophila melanogaster.

Akif M, Masuyer G, Bingham RJ, Sturrock ED, Isaac RE, Acharya KR.

FEBS J. 2012 Dec;279(24):4525-34. doi: 10.1111/febs.12038. Epub 2012 Nov 22.

27.

Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides.

Masuyer G, Schwager SL, Sturrock ED, Isaac RE, Acharya KR.

Sci Rep. 2012;2:717. doi: 10.1038/srep00717. Epub 2012 Oct 9.

28.

Scientific letter: Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) and Galectin-3 levels in tuberculous pericardial effusion: implications for pathogenesis and prevention of pericardial constriction.

Ntsekhe M, Matthews K, Wolske J, Badri M, Wilkinson KA, Wilkinson RJ, Sturrock ED, Mayosi BM.

Heart. 2012 Sep;98(17):1326-8. doi: 10.1136/heartjnl-2012-302196. Epub 2012 Jul 26. No abstract available.

29.

Shedding the load of hypertension: the proteolytic processing of angiotensin-converting enzyme.

Ehlers MR, Gordon K, Schwager SL, Sturrock ED.

S Afr Med J. 2012 Mar 2;102(6):461-4. Review.

PMID:
22668937
30.

New ketomethylene inhibitor analogues: synthesis and assessment of structural determinants for N-domain selective inhibition of angiotensin-converting enzyme.

Sharma RK, Douglas RG, Louw S, Chibale K, Sturrock ED.

Biol Chem. 2012 May;393(6):485-93. doi: 10.1515/hsz-2012-0127.

PMID:
22628311
31.

Structure based drug design of angiotensin-I converting enzyme inhibitors.

Anthony CS, Masuyer G, Sturrock ED, Acharya KR.

Curr Med Chem. 2012;19(6):845-55. Review.

PMID:
22214449
32.

An angiotensin I-converting enzyme mutation (Y465D) causes a dramatic increase in blood ACE via accelerated ACE shedding.

Danilov SM, Gordon K, Nesterovitch AB, Lünsdorf H, Chen Z, Castellon M, Popova IA, Kalinin S, Mendonca E, Petukhov PA, Schwartz DE, Minshall RD, Sturrock ED.

PLoS One. 2011;6(10):e25952. doi: 10.1371/journal.pone.0025952. Epub 2011 Oct 5.

33.

The significance of the C(α) substituent in the selective inhibition of matrix metalloproteinases 1 and 9.

Domingo R, Chibale K, Sturrock ED.

Biol Chem. 2011 Nov;392(11):1003-10. doi: 10.1515/BC.2011.165.

PMID:
21972974
34.

Structural characterization of angiotensin I-converting enzyme in complex with a selenium analogue of captopril.

Akif M, Masuyer G, Schwager SL, Bhuyan BJ, Mugesh G, Isaac RE, Sturrock ED, Acharya KR.

FEBS J. 2011 Oct;278(19):3644-50. doi: 10.1111/j.1742-4658.2011.08276.x. Epub 2011 Sep 8.

35.

Novel mechanism of inhibition of human angiotensin-I-converting enzyme (ACE) by a highly specific phosphinic tripeptide.

Akif M, Schwager SL, Anthony CS, Czarny B, Beau F, Dive V, Sturrock ED, Acharya KR.

Biochem J. 2011 May 15;436(1):53-9. doi: 10.1042/BJ20102123.

36.

The N domain of human angiotensin-I-converting enzyme: the role of N-glycosylation and the crystal structure in complex with an N domain-specific phosphinic inhibitor, RXP407.

Anthony CS, Corradi HR, Schwager SL, Redelinghuys P, Georgiadis D, Dive V, Acharya KR, Sturrock ED.

J Biol Chem. 2010 Nov 12;285(46):35685-93. doi: 10.1074/jbc.M110.167866. Epub 2010 Sep 8.

37.

Crystal structure of a phosphonotripeptide K-26 in complex with angiotensin converting enzyme homologue (AnCE) from Drosophila melanogaster.

Akif M, Ntai I, Sturrock ED, Isaac RE, Bachmann BO, Acharya KR.

Biochem Biophys Res Commun. 2010 Jul 30;398(3):532-6. doi: 10.1016/j.bbrc.2010.06.113. Epub 2010 Jul 1.

PMID:
20599761
38.

High-resolution crystal structures of Drosophila melanogaster angiotensin-converting enzyme in complex with novel inhibitors and antihypertensive drugs.

Akif M, Georgiadis D, Mahajan A, Dive V, Sturrock ED, Isaac RE, Acharya KR.

J Mol Biol. 2010 Jul 16;400(3):502-17. doi: 10.1016/j.jmb.2010.05.024. Epub 2010 May 19.

PMID:
20488190
39.

Spectroscopic and structural analysis of somatic and N-domain angiotensin I-converting enzyme isoforms from mesangial cells from Wistar and spontaneously hypertensive rats.

de Andrade MC, Affonso R, Fernandes FB, Febba AC, da Silva ID, Stella RC, Marson O, Jubilut GN, Hirata IY, Carmona AK, Corradi H, Acharya KR, Sturrock ED, Casarini DE.

Int J Biol Macromol. 2010 Aug 1;47(2):238-43. doi: 10.1016/j.ijbiomac.2010.04.015. Epub 2010 May 8.

PMID:
20435057
40.

Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril.

Watermeyer JM, Kröger WL, O'Neill HG, Sewell BT, Sturrock ED.

Biochem J. 2010 Apr 28;428(1):67-74. doi: 10.1042/BJ20100056.

PMID:
20233165
41.

A computational approach to the study of the binding mode of dual ACE/NEP inhibitors.

Dimitropoulos N, Papakyriakou A, Dalkas GA, Sturrock ED, Spyroulias GA.

J Chem Inf Model. 2010 Mar 22;50(3):388-96. doi: 10.1021/ci9005047.

PMID:
20170101
42.

Fine epitope mapping of monoclonal antibodies 9B9 and 3G8 to the N domain of angiotensin-converting enzyme (CD143) defines a region involved in regulating angiotensin-converting enzyme dimerization and shedding.

Gordon K, Balyasnikova IV, Nesterovitch AB, Schwartz DE, Sturrock ED, Danilov SM.

Tissue Antigens. 2010 Feb;75(2):136-50. doi: 10.1111/j.1399-0039.2009.01416.x. Epub 2009 Dec 7.

PMID:
20003136
43.

Inhibition of zinc metallopeptidases in cardiovascular disease--from unity to trinity, or duality?

Dive V, Chang CF, Yiotakis A, Sturrock ED.

Curr Pharm Des. 2009;15(31):3606-21. Review.

PMID:
19925415
44.

Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-converting enzyme.

Kröger WL, Douglas RG, O'Neill HG, Dive V, Sturrock ED.

Biochemistry. 2009 Sep 8;48(35):8405-12. doi: 10.1021/bi9011226.

PMID:
19658433
45.

Catalytic properties of recombinant dipeptidyl carboxypeptidase from Escherichia coli: a comparative study with angiotensin I-converting enzyme.

Cunha CE, Magliarelli Hde F, Paschoalin T, Nchinda AT, Lima JC, Juliano MA, Paiva PB, Sturrock ED, Travassos LR, Carmona AK.

Biol Chem. 2009 Sep;390(9):931-40. doi: 10.1515/BC.2009.105.

PMID:
19558329
46.

The role of glycosylation and domain interactions in the thermal stability of human angiotensin-converting enzyme.

O'Neill HG, Redelinghuys P, Schwager SL, Sturrock ED.

Biol Chem. 2008 Sep;389(9):1153-61. doi: 10.1515/BC.2008.131.

PMID:
18713002
47.

Epitope mapping of mAbs to denatured human testicular ACE (CD143).

Balyasnikova IV, Metzger R, Franke FE, Conrad N, Towbin H, Schwartz DE, Sturrock ED, Danilov SM.

Tissue Antigens. 2008 Oct;72(4):354-68. doi: 10.1111/j.1399-0039.2008.01112.x. Epub 2008 Aug 12.

PMID:
18700874
48.

Mapping of conformational mAb epitopes to the C domain of human angiotensin I-converting enzyme.

Naperova IA, Balyasnikova IV, Schwartz DE, Watermeyer J, Sturrock ED, Kost OA, Danilov SM.

J Proteome Res. 2008 Aug;7(8):3396-411. doi: 10.1021/pr800142w. Epub 2008 Jun 25.

PMID:
18576678
49.

Probing the basis of domain-dependent inhibition using novel ketone inhibitors of Angiotensin-converting enzyme.

Watermeyer JM, Kröger WL, O'Neill HG, Sewell BT, Sturrock ED.

Biochemistry. 2008 Jun 3;47(22):5942-50. doi: 10.1021/bi8002605. Epub 2008 May 6.

PMID:
18457420
50.

Glycosylation of prothrombin fragment 1 governs calcium oxalate crystal nucleation and aggregation, but not crystal growth.

Webber D, Rodgers AL, Sturrock ED.

Urol Res. 2007 Dec;35(6):277-85. Epub 2007 Nov 7.

PMID:
17987287

Supplemental Content

Loading ...
Support Center